Evolus Reports 21.2% Revenue Growth to $84.1 Million in Q2 2026

Evolus, Inc. reported its financial results for the second quarter of 2026, revealing a net revenue of $84.1 million, a 21.2% increase from $69.4 million in the same period last year. The growth was primarily driven by higher sales of its flagship product, Jeuveau®, which generated $74.5 million in revenue, up from $59.0 million in the prior year. The company also recorded a gross profit of $57.2 million, resulting in a gross profit margin of 68.0%, compared to 65.3% in the previous year. Despite the revenue increase, Evolus reported a net loss of $8.1 million for the quarter, an improvement from the $17.1 million loss recorded in Q2 2025.

For the first half of 2026, Evolus achieved total net revenues of $157.2 million, up 14.0% from $137.9 million in the same period of 2025. The company’s cost of goods sold increased to $51.1 million, reflecting higher product volumes, but was partially offset by a $1.1 million reduction due to recognized tariff refunds. The net loss for the six months ended June 30, 2026, was $18.7 million, a significant reduction from the $36.0 million loss reported in the first half of 2025.

Strategically, Evolus has made significant advancements, including the launch of four Evolysse® products in Europe in May 2026 and the anticipated approval of two additional Evolysse® products in the U.S. in 2026 and 2027. The company also entered into a License, Supply and Distribution Agreement with IBSA for the exclusive rights to develop and commercialize Profhilo®, an injectable hyaluronic acid product, in the U.S. This agreement is expected to enhance Evolus's product portfolio in the aesthetics market.

Operationally, Evolus reported an increase in its customer base and engagement metrics, which contributed to the revenue growth. The company’s cash and cash equivalents stood at $45.2 million as of June 30, 2026, with an accumulated deficit of $679.8 million. Evolus continues to face challenges, including potential tariffs on its products and the need for ongoing capital to support its operations and product development. The company anticipates that its current capital resources, along with future cash generated from operations, will be sufficient to fund its operations for at least the next twelve months.